BIO Announces Program for 2007 BIO InvestorForum </a>

WASHINGTON, D.C. (September 6, 2007) -- The Biotechnology Industry Organization (BIO) announces a comprehensive program planned for the 2007 BIO InvestorForum, which will include leading experts discussing treatments for the most prevalent diseases. The conference, hosted by BIO and supported by Pacific Growth Equities; Acumen BioFin, a Division of Rodman & Renshaw; Jefferies & Company; RBC Capital; and Bank of America, will take place October 9-11, at the Palace Hotel in San Francisco, Calif.

“This year’s conference program includes a broad cross section of investors, company representatives, and leading academic researchers who will provide tremendous insights into new product development progress, emerging data from clinical-stage candidates, and the financing and business development trends driving investment in the industry,” said Alan Eisenberg, executive vice president for Emerging Companies and Business Development at BIO. 

Sessions include:

·         Hepatitis C - Where Are We Really Going with Future Treatment Paradigms?                                                        
Moderator Jay S. Markowitz, M.D., vice president, investment analyst, T. Rowe Price Company
This panel will address the unmet medical need in HCV therapy and the potential that direct antivirals and next-generation interferons have in improving the efficacy and tolerability of treatment and in offering patients a sustained viral response.

·         Obesity Management - The Thick and Thin of New Targets and Treatments                                                 
Moderator Liana Moussatos, Ph.D., senior healthcare research analyst, Pacific Growth Equities, LLC
Panelists will review the lessons companies and investors can learn from past failures to apply to the clinical-stage drug candidates today and discuss promising approaches for chemical weight control.

·         The Odd Couple - Marrying Chemotherapy with Targeted Therapies                                     
Moderator David Parkinson, M.D., senior vice president of Oncology Research and Development, Biogen Idec
This panel will focus on current development issues, including how to pick the best combinations of therapies and what we are seeing in the clinic with these new investigative regimens across cancers.

·         Alzheimer’s Disease – Novel Mechanisms and Targets Renewing the Future for Patients  
Moderator Elemer Piros, Ph.D., senior biotechnology analyst, Acumen BioFin, a Division of Rodman & Renshaw
Panelists will discuss new therapies for Alzheimer’s disease, which are moving from lab to clinic, addressing novel targets, the underlying mechanisms of disease and its pathology. 

Now in its fourth year, the BIO InvestorForum plays host to public and private equity investors, research analysts, investment bankers and senior-level industry executives focused on investment trends and business development opportunities in the life sciences. The conference will include more than 225 public and venture-stage company presentations, eight therapeutic workshops on drug and technology developments, six roundtables on the latest market and investment opportunities, one-on-one investor meetings and numerous networking opportunities.


For the complete program and registration information, please visit  Registration is complimentary for credentialed members of the media.


Upcoming BIO Events

BIO Mid-America VentureForum 2007
September 24-26, 2007
Milwaukee, Wis.

BIO-Europe 2007 International Partnering Conference
November 12-14, 2007
Hamburg, Germany

Pacific Rim Summit on Industrial Biotechnology and Bioenergy
November 14-16, 2007
Honolulu, Hawaii

2008 BIO International Convention
June 17-20, 2008
San Diego, Calif.


Visit for more information on all upcoming events.



BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.